MedTrace Logo

Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures

NCT06084689 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2025-09-02

No results posted yet for this study

Summary

Phase II, multicenter, open-label, multi-cohort proof-of-concept study designed to evaluate the safety and efficacy of Ezabenlimab combined with BI 907828 in patients with unresectable, locally advanced or metastatic solid tumors.

Conditions

Interventions

DRUG

Ezabenlimab + BI907828

A treatment cycle consists of 3 weeks. Both treatments will be administered on Day 1 of each cycle.

Sponsors & Collaborators

Principal Investigators

  • Antoine ITALIANO, MD, PhD · Institut Bergonié

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-14
Primary Completion
2024-07-01
Completion
2024-07-01

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06084689 on ClinicalTrials.gov